AMN107 (nilotinib): a new treatment for resistant leukaemia
Author Information
Author(s): Erica Weisberg, Paul Manley, Jelena Mestan, Stefan Cowan-Jacob, Amit Ray, James D. Griffin
Primary Institution: Dana Farber Cancer Institute
Hypothesis
AMN107 was designed to be more effective than imatinib against BCR-ABL mutations causing drug resistance.
Conclusion
AMN107 shows promise in treating patients with chronic myelogenous leukaemia who are resistant to imatinib.
Supporting Evidence
- AMN107 is more potent than imatinib against wild-type BCR-ABL.
- AMN107 is effective against 32 out of 33 imatinib-resistant BCR-ABL mutants.
- Clinical trials showed significant responses in CML patients resistant to imatinib.
Takeaway
AMN107 is a new medicine that helps people with a type of blood cancer when other medicines don't work anymore.
Methodology
The study involved a Phase I/II clinical trial with patients who were resistant to imatinib.
Potential Biases
Several authors are employed by Novartis, the company that developed AMN107.
Limitations
Some patients did not respond to AMN107, especially those with advanced disease.
Participant Demographics
Included patients with chronic, accelerated, and blast-phase CML, as well as Ph+ ALL patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website